A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
about
Antigen-specific active immunotherapy for ovarian cancerTrial WatchIs the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.Phase I dendritic cell p53 peptide vaccine for head and neck cancer.The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancerPast, present and future targets for immunotherapy in ovarian cancerPeptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantImmunotherapy for ovarian cancer.A view on dendritic cell immunotherapy in ovarian cancer: how far have we come?Overexpressed oncogenic tumor-self antigensLow Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial.Trial watch: Dendritic cell-based interventions for cancer therapyImmunotherapy in ovarian cancer.Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12.HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.The changing landscape of therapeutic strategies for recurrent ovarian cancer.Next-generation peptide vaccines for advanced cancer.Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.Dendritic cell immunotherapy in ovarian cancer.A review of dendritic cell therapy for cancer: progress and challenges.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy.Cellular immunotherapy of cancer: an overview and future directions.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.Understanding dendritic cell immunotherapy in ovarian cancer.p53-reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy.Clinical trials in gynecologic oncology: Past, present, and future.Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.Cancer Vaccines in Ovarian Cancer: How Can We Improve?
P2860
Q24193567-5A5E33C3-8871-4E1D-A78D-6D96793E0892Q24618653-1275E729-634D-441F-9825-1013325EF79BQ30370848-2C8DAC9D-4C57-4286-8541-FFA027A9EA45Q30409053-569CDBE2-D33C-4CE8-9275-58220F31844BQ30414395-ACB42CF2-C534-4F79-93A5-E3A653F04DBEQ30577847-6093991A-2D05-4073-878D-8D1ABEAE82F9Q33939202-35A34042-E29B-4F7D-83F1-49866CB64E6FQ35034010-E12657AF-60D1-456F-9C33-F506F917E22BQ35125382-382ED451-3CA0-4DFE-A6EF-DE74A430FF10Q35164189-6C6F3551-B29C-4366-A8D4-E9781521E181Q35475233-2EB9D4DB-F00E-40E6-B2DC-F8FB4BE1E74FQ35886756-C5BE6955-E147-4524-8B0A-A2779AA87371Q36021163-CE65DD7D-D337-43AE-BD75-90DDFBF63E86Q36302848-CA9F5632-5A8C-4169-A82D-4AFB87BE3FB3Q36388529-651643C9-E30C-46CF-942E-A4CA81558633Q36631249-D704BA11-49B4-4D44-92DD-05F4B0A9AC09Q36821184-DA62BB8B-6363-4E61-BB72-1A8BA0E82178Q37012697-F378694E-88E4-4040-A9D2-36413DCB628FQ37564665-FEBDA4F3-0536-4F4A-AA24-0B34D6C4748DQ38031280-753383B2-9855-4D40-A122-C10293BF46DFQ38048887-9203DC72-E373-4DE1-A1F1-35E92873F322Q38056246-1CA74F47-A3D3-418E-86C2-FC16319EEBF1Q38059513-8B0D22AE-988F-4FCB-A4B1-D4FE7C18E6FDQ38069183-A8B750E7-BCBF-4E25-89C7-56A0BC6D7D50Q38099612-BD57C0E4-A863-403F-BEA6-976AF1E03E24Q38168904-87DF905B-70D6-4C49-B225-1411D093244FQ38395925-DB2ECF1D-EB61-4248-9E30-58649348AC27Q38673161-1C7D5766-A240-460E-B1E2-B5D399C5279CQ38715211-F155E2CE-0462-48B7-B161-FAEE649600C6Q38808249-C2451DFE-4E78-455E-BE87-E16C23154A54Q47561666-2A7E8793-B216-4F73-8501-C943E9491414Q47796770-585079A9-4A15-4E81-8C15-112B0DBAF427Q53009456-DD751CB2-680B-4196-B2C4-3F4EC83DA8A5Q54385315-63DA9539-6BC4-43A7-8345-86A0FA136ADF
P2860
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A gynecologic oncology group p ...... e risk ovarian cancer patients
@en
A gynecologic oncology group p ...... risk ovarian cancer patients.
@nl
type
label
A gynecologic oncology group p ...... e risk ovarian cancer patients
@en
A gynecologic oncology group p ...... risk ovarian cancer patients.
@nl
prefLabel
A gynecologic oncology group p ...... e risk ovarian cancer patients
@en
A gynecologic oncology group p ...... risk ovarian cancer patients.
@nl
P2093
P2860
P1476
A gynecologic oncology group p ...... e risk ovarian cancer patients
@en
P2093
Albert B Deleo
Carmen Visus
Eva Wieckowski
Jay A Berzofsky
Jeffrey G Bell
Judith K Wolf
Malgorzata Czystowska
Maria Merino
Marta E Szajnik
P2860
P2888
P304
P356
10.1007/S00262-011-1100-9
P577
2011-09-17T00:00:00Z